TNDM Tandem Diabetes Care
- 40.050
- -0.600-1.48%
Tandem Diabetes Care News
DexCom Reaches a Multi-year Low as Downgrades Follow Guidance Cut
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
DexCom, Deckers, Ford, Nvidia, Alphabet, Coursera, Bristol Myers, 3M, and More Stock Market Movers
Why Ultra Clean Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Ozempic's Success Could Stifle Demand for Diabetes-Related Devices -- Market Talk
Trending Stocks Today | BurgerFi International Soars 142.6% Post-Market
An Insider At Tandem Diabetes Care Lowered Their Holding Recently
Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024
Glaukos Cut as Citi Reviews U.S. MedTechs
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $57
Understanding Tandem Diabetes Care: Joanne Wuensch's Investment Perspective
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Stifel Nicolaus Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
Wells Fargo Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $50
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Tandem Diabetes, DexCom See Weakness Following ADA Conference
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Analysis
Price Target
No Data
